Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Rapport Therapeutics Inc.

Clinical trials sponsored by Rapport Therapeutics Inc., explained in plain language.

Rapport Therapeutics Inc. RAPP NASDAQ

A biopharmaceutical company developing precision medicines for neurological disorders.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 3 Not yet finished but already full! 1 Completed 1

New pill RAP-219 aims to tame mania in bipolar disorder

Symptom relief Ongoing

This study tests an experimental drug called RAP-219 for people with bipolar I disorder who are currently experiencing a manic episode. About 250 participants will receive either RAP-219 or a placebo daily for 21 days. Researchers will measure changes in manic symptoms using a st…

Phase: PHASE2 • Sponsor: Rapport Therapeutics Inc. • Aim: Symptom relief

Last updated Aug 12, 2026 00:00 UTC